Login to Your Account



Cerenis Testing rHDL Product in 500-Patient Phase II Trial

By Nuala Moran


Wednesday, March 16, 2011
LONDON – Cerenis Therapeutics SA is taking a huge bet on a Phase II trial of its recombinant high density lipoprotein (rHDL) product CER-001 in reducing cholesterol, announcing the start of a 500-patient U.S. and European study in patients with acute coronary syndrome. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription